BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Risvutatug rezetecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Risvutatug rezetecan\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06699576-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT06699576)
DESCRIPTION:Risvutatug rezetecan\, phase 1.\nStudy: ARTEMIS-103: Phase 1b S
 tudy of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcom
 a.\nEstimated primary completion: 30 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06699576
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462923-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT07462923)
DESCRIPTION:Risvutatug rezetecan\, phase 1.\nStudy: HS-20093 in Patients Wi
 th Advanced Gastric and Gastroesophageal Junction Adenocarcinoma\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07462923
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268053-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT07268053)
DESCRIPTION:Risvutatug rezetecan\, phase 1.\nStudy: A Phase 0/1 Clinical Tr
 ial With an Expansion Phase of GSK5764227\, a B7-H3-Targeted Antibody-Drug
  Conjugate (ADC)\, in Patients With Recurrent Grade 4 Glioma and Patients 
 With Brain Metastases\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07268053
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602777-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07602777)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study Evaluating th
 e Efficacy and Safety of Risvutatug Rezetecan in Participants With Advance
 d Sarcomas (EMBOLD Sarcoma-202)\nEstimated primary completion: 5 November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07602777
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099898-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07099898)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Canc
 er (SCLC) [EMBOLD SCLC-301]\nEstimated primary completion: 5 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 099898
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526624-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT06526624)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Small Cell Lung Cancer.\nStudy
 : A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell L
 ung Cancer\nEstimated primary completion: 30 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06526624
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115446-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT07115446)
DESCRIPTION:Risvutatug rezetecan\, phase 1.\nStudy: Phase Ib Study of HS-20
 093+HRS-5041 in Patients With Advanced Prostate Cancer\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/risvutatug-rezetecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07115446
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899086-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT07899086)
DESCRIPTION:Risvutatug rezetecan\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase I Study of HS-20093 Injection in Combination Therapy in Non-
 Small Cell Lung Cancer\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezetecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078990
 86
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277270-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT07277270)
DESCRIPTION:Risvutatug rezetecan\, phase 1.\nStudy: A Study of GSK5764227 i
 n Combination With Standard of Care (SoC) or Other Agents in Participants 
 With Advanced Solid Tumors\nEstimated primary completion: 14 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 277270
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824882-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Risvutatug rezetecan: Phase 2 readout est. (NCT07824882)
DESCRIPTION:Risvutatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase II Study of HS-20093 Injection Combined With Adebrelimab Ver
 sus HS-20093 Injection in Previously Treated Patients With Advanced or Met
 astatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic
  Alterations\nEstimated primary completion: 30 March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07824882
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736612-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07736612)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Pan-RAS Inhibitor i
 n Combination With Anti-Tumor Therapy in Participants With Advanced Pancre
 atic Cancer\nEstimated primary completion: 30 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07736612
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892625-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT07892625)
DESCRIPTION:Risvutatug rezetecan\, phase 1\, Small Cell Lung Cancer.\nStudy
 : A Phase I Study of HS-20093 in Combination With ZG006 With or Without Ad
 ebrelimab in Patients With ES-SCLC\nEstimated primary completion: 15 Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug
 -rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07892625
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230106-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Risvutatug rezetecan: Phase 2 readout est. (NCT07230106)
DESCRIPTION:Risvutatug rezetecan\, phase 2.\nStudy: A Study of SHR3680\, HS
 -20093 and SHR2554 in Subjects With Prostate Cancer\nEstimated primary com
 pletion: December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/risvutatug-rezetecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07230106
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963502-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Risvutatug rezetecan: Phase 1 readout est. (NCT06963502)
DESCRIPTION:Risvutatug rezetecan\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therap
 ies in Patients With Advanced Solid Tumors\nEstimated primary completion: 
 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ris
 vutatug-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06963502
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464327-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07464327)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Ve
 rsus Docetaxel in Previously Treated Patients With Advanced or Metastatic 
 Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterat
 ions\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07464327
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885034-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT06885034)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study to Test the S
 afety and Effectiveness of GSK5764227\, Alone or With Other Treatments\, i
 n Participants With Advanced Gastrointestinal Cancers That Cannot be Surgi
 cally Removed (EMBOLD PanGI-201)\nEstimated primary completion: 9 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06885034
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602855-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20290622
DTEND;VALUE=DATE:20290623
SUMMARY:Risvutatug rezetecan: Phase 1/2 readout est. (NCT07602855)
DESCRIPTION:Risvutatug rezetecan\, phase 1/2.\nStudy: A Study of Risvutatug
  Rezetecan in Combination With Ivonescimab in Participants With Advanced S
 olid Tumors (EMBOLD PanTumour-103)\nEstimated primary completion: 22 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-reze
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07602855
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802704-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20291205
DTEND;VALUE=DATE:20291206
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07802704)
DESCRIPTION:Risvutatug rezetecan\, phase 3.\nStudy: A Study of Risvutatug R
 ezetecan in Participants With Metastatic Castration-resistant Prostate Can
 cer (mCRPC) [EMBOLD Prostate-302]\nEstimated primary completion: 5 Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-re
 zetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07802704
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07408063-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Risvutatug rezetecan: Phase 2 readout est. (NCT07408063)
DESCRIPTION:Risvutatug rezetecan\, phase 2.\nStudy: A Comprehensive Multiom
 ic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechani
 sms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck
  Squamous Cell Carcinoma (HNSCC)\nEstimated primary completion: 30 June 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/risvutatug-rezete
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07408063
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621601-2501@assetmemo.bio
DTSTAMP:20261121T005741Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07621601)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Esophageal Squamous Cell Carci
 noma.\nStudy: A Study of HS-20093 in Patients With Pretreated Advanced or 
 Metastatic Esophageal Squamous Cell Carcinoma (ESCC)\nEstimated primary co
 mpletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/risvutatug-rezetecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07621601
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
